Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK513026 Pneumococcal Vaccine in Healthy Elderly
NCT00307528Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2004
- Primary completion
- Mar 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of 11-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD) and pneumonia, sponsored by GSK. Primary endpoints: Occurrence, intensity and relationship of any solicited local and general signs and symptoms, Occurrence, intensity and relationship to vaccination of unsolicited local and general signs and symptoms and 2 more. Started Jan 2004; status: completed.
02
Drugs
11-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)pneumonia
Beyond the preview
Go deeper on NCT00307528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307528.